What are the indications, rationale, advantages, required pre‑irradiation evaluation, and toxicities of total body irradiation (TBI) as a conditioning regimen for hematopoietic stem‑cell transplantation?

Total Body Irradiation (TBI) for Hematopoietic Stem Cell Transplantation

TBI serves as a conditioning regimen prior to allogeneic and autologous hematopoietic stem cell transplantation, functioning both as a cytotoxic agent to eliminate malignant disease and as an immunosuppressant to prevent graft rejection. 1, 2

Indications

TBI-based conditioning regimens are indicated for:

• Allogeneic HSCT for hematologic malignancies, including acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndromes 3
• Sickle cell disease in adults where nonmyeloablative regimens based on low-dose TBI (≤400 cGy) can be used as an alternative to chemotherapy-based conditioning 4
• Hodgkin's lymphoma patients at high risk of relapse who have not been previously irradiated, as part of autologous stem cell transplantation conditioning 5
• Multiple sclerosis when intermediate-intensity protocols like cyclophosphamide-TBI-ATG are employed, though this is less commonly used than chemotherapy-based regimens 6

Rationale

The fundamental rationale for TBI includes:

• Superior tissue penetration independent of vascular supply, allowing effective treatment of sanctuary sites (CNS, testes, orbits) that chemotherapy cannot adequately reach 2, 7
• Dual mechanism of action: cytotoxic elimination of residual malignant cells while creating marrow space, combined with immunosuppression to facilitate donor cell engraftment 1, 2
• Uniform dose distribution throughout the body, unaffected by physiologic barriers such as renal or hepatic function 2
• Potential for disease reversal in conditions like sickle cell disease, particularly in adults with organ damage where myeloablative chemotherapy poses excessive toxicity risk 4

Advantages

Key advantages of TBI over chemotherapy-alone conditioning:

• Greater tumor cytotoxicity with better penetration to poorly vascularized areas 2
• Fertility preservation potential with low-dose TBI (≤400 cGy), particularly preserving male gonadal function when testicular shielding is employed 4
• Enables transplantation in adults with accumulated organ damage who cannot tolerate myeloablative chemotherapy 4
• No dependence on blood-brain barrier or perfusion limitations 1

Evaluation Before TBI

Prior to initiating TBI-based conditioning, comprehensive assessment must include:

Fertility Assessment

• Measure follicle-stimulating hormone, luteinizing hormone, estradiol, and anti-Müllerian hormone in women; testosterone in men 6
• Refer to reproductive endocrinology for counseling and fertility preservation options for both sexes 6
• Consider gonadotropin-releasing hormone agonist treatment in women to attenuate premature menopause risk 6

Disease and Transplant-Specific Factors

• Assess prior radiation exposure, particularly thoracic irradiation, as this increases post-transplant mortality risk especially when administered within 50 days of transplant 5
• Evaluate disease chemosensitivity, as this remains a major predictor of transplant outcome 5
• Document organ function, particularly in adults with sickle cell disease who may have accumulated end-organ damage 4
• Determine HLA matching status and donor availability 3

Risk Stratification

• Identify patients at high risk for graft failure or rejection based on disease type and prior treatments 3
• Assess comorbidities that may increase treatment-related mortality 4

Toxicity

Acute Toxicities

• Increased treatment-related morbidity and mortality compared to chemotherapy-alone regimens 2
• Pulmonary toxicity, particularly when thoracic radiation is included or when large lung volumes are in the target field 5, 7
• Radiation myelitis risk when spinal cord is in the radiation field, especially with busulfan-containing regimens that cross the blood-brain barrier 5

Long-Term Toxicities

• Secondary malignancies, including myelodysplastic syndrome and acute leukemia, though attribution is difficult as these occur with chemotherapy-based regimens and in untransplanted sickle cell disease patients as well 4
• Gonadal dysfunction and infertility, particularly in females who experience worsening of pre-existing ovarian dysfunction with standard-dose TBI 4
• Growth retardation in pediatric patients 7
• Increased nonrelapse mortality with higher TBI doses: 5-year NRM of 28% with 12 Gy, 32% with 13-13.75 Gy, and 34% with 14 Gy 8

Dose-Dependent Considerations

• Higher doses (>12 Gy) increase NRM without survival benefit despite reducing disease relapse 8
• Low-dose TBI (≤400 cGy) preserves fertility better but may carry uncertain risk of secondary malignancies 4

Technical Challenges

• Dose heterogeneity remains a significant technical problem with traditional 2D TBI techniques 1, 7
• Coordination complexity between hematology and radiation oncology departments 2

Critical Caveats

The long-term effects of low-dose TBI in allogeneic HSCT remain uncertain, with very low certainty evidence supporting its use 4. The balance of benefits versus harms favors neither low-dose TBI nor chemotherapy-based conditioning definitively 4. Modern techniques like total marrow irradiation (TMI) and total marrow and lymphoid irradiation (TMLI) offer more selective targeting with better normal tissue sparing, though these require advanced technology and expertise 9, 7. Despite improvements in supportive care, myeloablative conditioning using higher TBI doses leads to worse outcomes without survival benefit 8.